PlasmaTech Biopharmaceuticals' Announces Initiation of Enrollment of MuGard Trial for Afinitor (Everolimus; Novartis) - Related Stomatitis at UCLA Breast Cancer Center
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, announced today that enrollment has begun in a clinical trial at UCLA's Jonsson Comprehensive Cancer Center that is evaluating MuGard in the prevention and treatment of stomatitis in breast cancer patients using everolimus (marketed by Novartis Oncology under the trade name Afinitor®).
View full press release